WO2017118995A1

WO2017118995A1 - An inhaler

Info

Publication number: WO2017118995A1
Application number: PCT/IN2016/050106
Authority: WO
Inventors: Bhupendra Kantilal RAVAL
Original assignee: Raval Bhupendra Kantilal
Priority date: 2016-01-07
Filing date: 2016-04-12
Publication date: 2017-07-13

Abstract

The present invention relates to the an inhaler. The present invention comprises of First assembly (FA; W1,E,N,P,W2); Second assembly (SA; A, A1, A4); Third assembly (TA) and a mouthpiece cap (MC). Said First Assembly (FA) is attached with said Second Assembly (SA) by fixing said Second Assembly in the passage (P) area of said First Assembly (FA) through said Third Assembly (i.e.the third assembly is the means used to attach the first and second assemblies). The present invention delivers exact dosage of medicine without the wastage of medicine and eliminates the risk of hurting the throat region of the infected person during intake of medicine.

Description

"AN INHALER"

FIELD OF THE INVENTION

The present improved inhaler relates to an improved inhaler. More, particularly the present improved inhaler relates to an improved inhaler that enables the infected person to inhale the medicine in exact dosage without wastage of medicine and eliminating the risk of hurting the throat region.

BACKGROUND OF THE INVENTION AND PRIOR ART

The advent of industrialization, use of automobiles, atomic reactors, green house gas emission and other human activities has led to an increase in pollution especially air pollution. The rise in air pollution is a leading cause for many respiratory disorders such as bronchitis, asthma, chronic obstructive pulmonary disease (COPD) or chronic sinusitis. This has invariably led to increase in use of related medicines such as steroid, corticosteroid, bronchodilator or a combination of these medicines to treat the ailment. People suffering from respiratory disorders are mainly dependent on inhalers containing such medicines for immediate relief and treatment of their ailment.

There are various types of inhalers which are available in market such as meter dose inhaler, pressurized meter dose inhalers, dry powder inhaler, nebulizer and analgizer, to treat the ailment of the infected person. Meter dose inhalers and pressurized meter dose inhalers are most common and widely used inhalers worldwide to treat various respiratory disorders. The key components of pressurized meter dose inhalers are canister containing propellants and medical formulation, and actuator. The canister is fitted into a plastic actuator which has a adapter, nozzle, passage and a mouthpiece for use by the infected person. The medicine is stored in the canister in the form of fine powder or liquid along with a propellant to fuel the medicine though the canister.

When the infected person presses the canister, the contents of canister release into the actuator in the form of aerosol. In the actuator, the aerosol passes through a nozzle towards passage to the mouthpiece end. The aerosol is then inhaled by the infected person. When this medicine reaches the lungs, it mixes with blood and provides relief. However, there are several disadvantages of the inhalers available in the market till date. (Fig. lA).

The process of puffing medicine from inhaler is known as actuation. When one puffs the medicine, the exact dose of medicine does not reach the throat. This is because the passage of the actuator is broad due to which upon actuation the aerosols do not travel in a straight path and spreads along the area of the passage of the actuator as shown in fig. 1A. Due to this during intake, some of the medicine spreads and sticks inside the mouth region of the infected person. The infected person then has to apply strenuous efforts to suck the medicine which is difficult for person suffering from respiratory disorder. Still some portion of the medicine remains stuck to walls of the passage area and some other portion to the mouth of the infected person. Thus, that portions of the medicine is not used for the treatment and is wasted. Hence, the conventional or existing inhalers fail to provide exact dosage released from the nozzle to the mouth of the person inhaling the medicine. Also, some of the aerosols stick inside the walls of the passage in the actuator. Over a period of time, improper handling and washing of inhaler allows various micro-organisms such as bacteria, fungus to grow inside the walls. This leads to contamination of the inhaler. Frequent use of such contaminated inhalers increases the risk of developing serious infections.

To overcome this problem, the applicant had developed an inhaler which has two restrictive walls a horizontal restricting wall (H) and grovel shaped restricting wall (G), as described in the patent no. 256590 (Fig. IB) . The horizontal restriction wall (H) covers whole area except the opening of adapter. The grovel shaped restricting wall (G) adjoins the nozzle. During actuation, these walls directs the aerosols towards passage and prevent deposition of medicine around nozzle region. Said invention prevents the contamination near and behind the nozzle. However, there is still scope to enhance the performance of the inhaler by restricting the deposition in the passage area and further preventing the infections more effectively.

Besides this, upon actuation the aerosols reaches the throat through the nozzle speedily which causes it to reach the throat with a speed higher than required. The intensity with which the aerosol strike in the throat of an infected person cause irritation of throat and hurt the throat region. Repeated use of conventional or existing meter dose inhalers may also cause sore throat or hoarse voice. Frequent use of inhaler may also cause oral candidiasis due to yeast/ fungal infection. These side-effects may become more painful condition for the person already suffering from respiratory disorder. Alternatively, spacer devices are available in the market which are attached externally with the actuators. Spacer devices are also known as 'add-on devices', 'accessory devices', 'extension devices' or 'holding chambers'. Spacers are hollow devices into which a dose of an inhaler's medicine formulation in the form of aerosol may be dispensed before it is inhaled by the infected person. The spacers are placed at the end of actuator and provides space between the mouthpiece end and infected person's mouth. The aerosols mixes with the air in the spacer device and slows down. This help to promote a proper inspiration for intake of medicine dose. Spacers thus help to reduce deposition of medicine in the throat region of an infected person. However, there are several disadvantages with use of spacer. In case of plastic spacers electrostatic charge may build-up on the spacer walls. This may retain the medicine inside the walls of the spacer thereby reducing the amount of dosage inhaled by the infected person. Multiple actuations for intake of prescribed dose by using plastic spacers leads to dosage variation. Therefore, frequent washing or alternatively use of metal spacers are generally recommended. However, these spacers may also allow various other organisms such as bacteria, fungus etc. to enter and thrive inside the walls thereby increasing the risk of contamination. Besides, spacer devices are available as large volume spacers and small volume spacers with volumes ranging from 20mL to 750mL in commercially available models. This makes them bulky in nature due to which, sometimes it become difficult to handle and cumbersome to carry these devices.

Thus, there is a need for an inhaler which delivers exact dose of drug in such a way that it does not hurt the throat region of an infected person, easy to handle and is also free of any other contamination or infection. DISADVANTAGES OF THE PRIOR ART ) Most of the existing inhalers fail to deliver exact amount of dose to the infected person. ) Most of the existing inhalers may allow deposition of medicine inside the walls of the passage which may lead to contamination. ) Most of the existing inhalers lead to excessive wastage of medicine during intake. ) Most of the existing inhaler increase the risk developing other infections which becomes more painful for the person already suffering from various respiratory disease. ) Most of the existing inhalers which are attached with spacers are expensive.

Most of the existing inhalers which are attached with spacers of varying sizes are not portable.

Most of the existing inhalers which are attached with spacers of varying sizes are difficult to handle. ) Most of the existing inhalers which are attached with spacers of varying sizes are cumbersome to use especially for children and elderly people suffering from various respiratory disease.

OBJECT OF THE INVENTION

The present invention relates to an improved inhaler that enables the infected person to inhale the medicine in exact dosage.

The present invention relates to an improved inhaler that do not lead to wastage of medicine.

The present invention relates to an improved inhaler that eliminates the risk of hurting throat region during intake of medicine.

The present invention provides an improved inhaler which is free from risk of any contamination. The present invention provides an improved inhaler which is user-friendly.

The present invention provides an improved inhaler which is cost-effective.

The present invention provides an improved inhaler which is portable.

The present invention provides an improved inhaler which is easy to handle. BRIEF DESCRIPTION OF DRAWINGS Shows conventional inhaler with conventional actuator

Shows conventional inhaler with restrictive actuator

Fragmented perspective view of present improved inhaler

Cross-section of fragmented perspective view of present improved inhaler

Cross-section of Actuator of present improved inhaler

Cross-section side view of present improved inhaler

Perspective view of attachment of present improved inhaler

Cross-sectional perspective view of attachment of present improved inhaler

Front view of attachment of present improved inhaler showing mouthpiece with two openings

Front view of the passage of the present improved inhaler showing the interlocking assembly

Shows the spread of the medicine in the mouth of the person using conventional inhaler

Shows the straight path of the medicine in the mouth of the person using present improved inhaler.

Meaning of Reference numerals of said component parts of present improved inhaler (I) Present improved inhaler

First Assembly

Actuator

Canister

Walls of the actuator

Adapter

Nozzle

Horizontal restricting wall

Grovel shaped restricting wall Passage

Walls of the passage

Second Assembly

Attachment

Nozzle Extension

Semicircular slot

First opening of semicircular slot

Second opening of semicircular slot

Striking area Semicircular block Mouthpiece Third Assembly

First slot Second slot

Male-Female mechanism Mouthpiece Cap Conventional Inhaler

DESCRIPTION OF THE INVENTION

The embodiment of the present invention provides an Improved Inhaler (I) . The present Improved Inhaler (I) enables the infected person to inhale the medicine in exact dosage without wastage of medicine and eliminating the risk of hurting the throat region.

Present improved inhaler (I) as shown in fig.2A and fig.2B mainly comprises of:

First Assembly (FA); Second Assembly (SA); Third Assembly (TA); and Mouthpiece Cap (MC). Wherein, Said First Assembly (FA) comprises of a Canister (C) and an Actuator (Ac).

Said Canister (C) contains medicine to be inhaled by the infected person; and it is fitted into an Actuator (Ac) . Said Actuator (Ac) is a conventional actuator or a restrictive actuator. Said conventional Actuator comprise of

Actuator walls (W l),

Adapter (E),

Nozzle (N),

Passage (P) and Passage wall (W2) .

Said Actuator Walls (Wl) form a hollow portion wherein said Canister (C) is placed. Said actuator has an adaptor (E) at its centre of wherein said Canister (C) is fitted with its opening downside. Said Nozzle (N) is adjacent to said Adapter (E) and the medicine is released from said Canister (C) through said Nozzle (N) when said canister (C) is pressed. Further, said Passage Walls (W2) form the hollow Passage (P) of the actuator facilitating the passage of medicine from the Nozzle (N) to the mouth of the person inhaling the medicine.

And Said restrictive actuator (as described and claimed in application number 1006 /MUM/ 2006) as shown in fig. IB comprise of:

Actuator walls (W l), Adapter (E), Nozzle (N),

Horizontal Restricting Wall (H), Grovel Shaped Restricting Wall (G), Passage (P) and

Passage wall (W2) .

Said Restrictive Actuator has a hollow structure with Actuator walls (Wl), wherein an adapter (E) is placed at the centre with said Nozzle (N) adjacent to it. Said Canister (C) is placed in said hollow structure between the Actuator Walls (Wl) with its opening downside and fitted in the adapter (E) . Said Nozzle (N) facilitates the medicine to be released from said Canister (C) when said canister (C) is pressed. Further, said Horizontal restricting wall (H) is placed inside the actuator (Ac) at the right angle to the plane of adapter (E). Said Horizontal restricting wall (H) is circular and adjoins to adapter (E) at the center and to the walls of the actuator (W l) at the periphery. Said Horizontal restricting wall (H) covers the whole area except the opening of the adapter (E) restricting the medicine to get diverted towards upper side of the actuator (Ac) or towards the Actuator Walls (Wl) . Further, said Grovel Shaped Restricting Wall (G) is placed which adjoins the nozzle (N) from one side and the walls of the passage (P) from other side inside the Actuator (Ac). This grovel shaped restricting wall (G) directs the medicine from the actuator(Ac) towards the mouthpiece (M) through the passage (P) .

Said Second Assembly (SA) comprises of an Attachment (A) with Nozzle Extension (Al),

Semicircular Slot (A2) with a striking area (a"), Semicircular block (A3); and

Mouthpiece (A4) with a first opening (a) and a second opening (a') .

Said Second Assembly (SA) is a detachable attachment (A) that is connected to said First Assembly (FA). Said Second Assembly (SA) has a Nozzle Extension (Al) that is fixed to the Nozzle (N) of the First Assembly (FA) through male-female joining mechanism (Ν'-ΑΓ) as shown in fig.4 thereby forming an extended Nozzle through which the medicine enters said Attachment (A) from the canister (C) when pressed. Said Attachment (A) further comprises of a Semicircular Slot (A2) with a striking area (a") around a Semicircular block (A3) wherein said semicircular slot (A2) ends in a first opening (a) and a second opening (a') in said mouth piece (A3) as shown in fig.5B.

Said Third Assembly (TA) is an interlocking assembly for interlocking said First Assembly (FA) and said Second Assembly (SA) as shown in fig.5C and fig.5D wherein said Third Assembly (TA) comprises of: a First Slot (S I) on the Passage wall (W2) of the Actuator (Ac) in said First Assembly (FA) and a Second Slot (S2) on said Attachment (A) of said Second Assembly (SA);

Wherein said first slot (S I) is elevated portion conjoined to passage area (P) of said actuator (Ac); wherein further said passage area (P) comprises of pair of said first slot (S I) placed on opposite side within said passage area (P) in parallel direction, placed equidistant from the end of the passage area (P) .

Wherein said second slot (S2) is elevated portion conjoined to said mouthpiece (A4) of the Attachment (A); wherein further second slot (S2) is placed in pair in parallel direction on opposite side on mouthpiece (A4) of the Attachment (A) .

Wherein further said first slot (S I) and said second slot (S2) are placed such that when said second assembly (SA) is placed in the passage area (P), said second assembly (SA) is pushed so as said second slot (S2) moves behind said first slot (S I) to interlock said first assembly (FA) and said second assembly (SA).

WORKING OF THE INVENTION

Said First Assembly (FA) with said Canister (C) fixed in said Actuator (Ac) is attached with said Second Assembly (SA) by fixing said Second Assembly (SA) in the passage (P) area of said First Assembly (FA) through said Third Assembly (TA) such that the nozzle (N) of the First Assembly (FA) and said Nozzle Extension (Al) are fixed. Said Improved Inhaler (I) is ready for inhaling medicine.

Said Improved Inhaler (I) is taken and said mouth piece (A4) is placed inside the mouth of the person using said Improved Inhaler (I) . Canister (C) of said First Assembly (FA) containing medicine is pressed. The medicine from said Canister (C), through Nozzle (N) passes towards the mouth of the person using said Improve Inhaler (I) through said Semicircular Slot (A2) wherein first the medicine strikes at the striking area (a") within said Semicircular Slot (A2) and then comes out of said first opening (a) and said second opening (a'). The speed with which the medicine is released from said Canister (C) through nozzle (N) is reduced once it strikes said striking area (a") within said Semicircular Slot (A2) from which the medicine comes out of said improved inhaler (I) through said first opening (a) and said second opening (a') and reaches the person's mouth and throat without hurting the throat.

COMPARATIVE STUDY OF CONVENTIONAL INHALER (I) WITH PRESENT IMPROVED INHALER (I):

A comparative study of conventional inhaler (CI) comprising of canister and actuator with the present improved inhaler(I) as described herein above was carried out to establish the advantages of the present invention. For this purpose, 200 Meter dose inhaler (As per Indian Medical standard) and present improved inhaler (I) with net weight of 12 gm of medicine each were tested under non-air circulation conditions. Both the inhalers were studied for determining the spread of medicine after pressing the canister (C) . In the conventional inhalers (CI) since the passage of the actuator is broad, the medicine spreads and does not travel in straight path upon actuation. On the other hand, in the present improved inhaler (I) the second assembly (SA) of the present invention provides it a semicircular slot (S I) which channelizes the path of the medicine (Fig.6A and Fig.6B) . The diameter of spreading of the medicine was studied by actuating both the inhalers from a distance of 1.5- 1.75 inch from a glass wall and the area covered by the released medicine was observed and the diameter was measured in each case. Following table compares the spread(diameter) of the dosage spray of the medicine from the conventional inhaler(CI) and the present improved inhaler(I).

Table 1. Comparison of spread of the dosage spray between conventional inhaler(CI) and present improved inhaler (I) .

The above table shows that the spread of the dosage spray is higher in conventional inhaler(CI) i.e. 1.0- 1.5 inch as compared to the present improved inhaler (I) i.e. 0.25 inch from each opening (a-a') . Along with the above table, referring to fig.6A and 6B, it can be clearly seen that the medicine when released from the conventional inhaler(CI) aerosols spread after coming out from the nozzle (N) and does not follow a straight path reaching to the throat of the person inhaling the medicine through it unlike that of the present invention. Due to this, during actuation, some of the medicine sticks to the walls of the passage (W2) and some other portion sticks inside the mouth region which results in wastage of medicine. The improvements introduced through the present invention has enabled developing present improved inhaler(I) that reduces the spread of the medicine released from the canister and enables it to be in a straight path reaching to the throat of the person inhaling the medicine using the present improved inhaler (I) . Further, as it does not spread, it neither sticks to the walls of the passage (W2) nor to the mouth of the person inhaling the medicine instead it makes the medicine to directly reach the throat of the person and thereby enabling inhalation of the medicine in exact dosage without wastage of medicine and preventing other infections.

In addition, as much of the medicine is wasted in the conventional inhaler(CI), one needs to take more number of puffs to control the symptom or treat the disorder. Thus, one needs more medicine. Instead, as described herein above, the present improved inhaler (I) enables exact dosage to be delivered to the throat region of the person inhaling the medicine. Thus, the present invention makes the treatment efficient and economical. A comparison was carried out for the same:

Table 2. Comparison of number of discharges between conventional inhaler(CI) and present improved inhaler (I) upon actuation.

The above table shows that number of discharges upon actuation is higher in the present improved inhaler (I) i.e. -230 as compared to conventional inhaler(CI) i.e. -215. In the conventional inhalers (CI), since some of the medicine is released due to leakage, it results in wastage of medicine and also increases the chances of contamination. Whereas, in the present improved inhaler(I) exact dosage of medicine is delivered which prevents wastage of medicine and reduces the chances of contamination. Besides, since number of discharges are more in the present improved inhaler(I), it also makes it cost-effective as compared to the conventional inhalers(I). Further, both the inhalers were studied for determining the distance travelled by the medicine away from the mouthpiece when the canister was pressed. The medicine requires to travel approximately 3.0-3.5 inch distance to reach the throat. However, the speed with which the dosage of the medicine is released from the mouthpiece, it travels a greater distance in case of the conventional inhaler(CI), which results in reaching of the medicine to the throat region with high speed hurting the throat region. Instead the improvements introduced through the present invention has enabled developing present improved inhaler (I) that reduces the speed of the medicine released from the canister (C) before it reaches to the throat of the person inhaling the medicine and thereby the distance travelled by the medicine away from the mouth piece (A4) is reduced.

Following table compares the distance travelled by the medicine from the conventional inhaler (CI) and the present improved inhaler(I):

Table 3. Comparison of distance of dosage spray between conventional inhaler(CI) and present improved inhaler(I).

From the above table, it can be seen that in the conventional inhaler (CI) the dosage spray travels to a greater length i.e. 17.0- 19.0 inch as compared to the present improved inhaler (I) i.e. 4.0-6.0 inch. Thus, the conventional inhaler(CI) cause the medicine to be released at a higher speed resulting in hurting of throat region. Also, it increase the chances of developing other serious infections. In comparison, reduced length of the present improved inhaler(I), delivers the medicine at a reduced speed thereby eliminating the risk of hurting the throat region and preventing infections.

Referring to above tables and fig.6A and 6B, it can be clearly seen that the spread of dosage spray is also narrower in the present improved inhaler (I) as compared to the conventional inhaler(CI) . This indicates that present improved inhaler is efficiently able to deliver the required dosage amount without any wastage of medicine and eliminates the risk of hurting the throat region. Also, the number of discharge in present improved inhaler (I) is less than the conventional inhaler (CI) . It can also be seen that the amount of medicine delivered through said number of discharges is less in present improved inhaler (I) than conventional inhaler(CI) . This indicates that the present improved inhaler (I) prevents excessive wastage of drug during intake and is therefore more cost-effective. Thus, the present improved inhaler (I) not only leads to effective treatment for the person suffering from respiratory disease but also reduces frequent actuations of drug to consume required dosage and is therefore, more user-friendly than the conventional inhaler(CI).

Comparative study between Conventional Inhaler(CI) attached with Spacer and Present Improved Inhaler (I) A comparative study was done between conventional inhaler(CI) comprising of canister (C) and actuator (Ac) which is attached to a spacer device and the present improved inhaler (I) as described herein above to establish the advantages of the present improved inhaler (I) over the said inhaler.

Sr.No. Features Conventional Present Improved

Inhaler (CI) + Inhaler(I)

Spacer 1 Attachment External Internal

2 Size Larger Regular (Same as standard inhaler)

3 Portability Cumbersome Easy

4 Handling Difficult Easy

5 Dosage delivered Varies Exact

6 Dosage variation Very high Negligible

7 Wastage of medicine High No wastage

8 Chances of High Low

contamination

9 User- friendliness Low High

10 Cost High Low

Table 5. Comparison between conventional inhaler (CI) + spacer and present improved inhaler (I)

Referring to table 5, the spacer is an external device and has a larger size than the present improved inhaler(I) which makes it difficult to carry and handle. Also, there is a possibility that during actuation, medicine will stick inside the walls of the spacer. This leads to variation in dosage amount of medicine. The infected person will then need to increase the number of actuations to consume the medicine resulting in wastage of medicine and increasing the risk of contamination. In comparison, the present improved inhaler (I) has a removable small attachment which is fitted inside the actuator (Ac) end which not only reduces the speed of the aerosol particles but also covers the nozzle end and prevent contamination. Owing to its small size and being internally placed in the inhaler it is easy to handle by infected person especially for children and elderly people. Also, it is easier to carry the attachment by infected person. The present improved inhaler(I) allows a consistent intake of dosage by the infected person. This helps to deliver exact dosage of medicine to the infected person thereby preventing dosage variation. Also, this helps to restrain need of excessive actuation thereby reducing wastage of medicine and preventing the chances of contamination. Since the attachment is small, it can be removed and cleaned easily. This makes the present improved inhaler(I) economical and user-friendly alternative compared to commercially available conventional inhaler (CI) attached with bulky spacers devices.

Having described what is considered the best form presently contemplated for embodying the present invention, various alterations, modifications, and / or alternative applications of the invention will be promptly apparent to those skilled in the art. Therefore, it is to be understood that the present invention is not limited to the practical aspects of the actual preferred embodiments hereby described and that any such modifications and variations must be considered as being within the spirit and the scope of the invention, as described in the above description.

CLAIMS: . An improved inhaler (I) mainly comprises of:

First Assembly (FA),

Second Assembly (SA),

Third Assembly (TA), and

Mouthpiece Cap (MC);

Wherein:

Said First Assembly (FA) further comprises of a Canister (C) and an Actuator (Ac) wherein Said Canister (C) contains medicine to be inhaled by the infected person; and it is fitted into an Actuator (Ac); further said Actuator (Ac) is a conventional actuator or a restrictive actuator; wherein further, said conventional Actuator comprise of:

Actuator walls (W l),

Adapter (E),

Nozzle (N),

Passage (P) and

Passage wall (W2);

said restrictive actuator (as described and claimed in application number 1006 /MUM/ 2006) comprise of:

Actuator walls (W l), Adapter (E),

Nozzle (N),

Horizontal Restricting Wall (H),

Grovel Shaped Restricting Wall (G),

Passage (P) and

Passage wall (W2) .

Said Mouth piece Cap (MC) is a cover for covering the mouthpiece (A4) of said inhaler when not in use to avoid dusting and unnecessary contamination in said inhaler.

wherein the improvement comprises of said second assembly (SA) and said third assembly (TA); wherein further:

Said Second Assembly (SA) comprises of an Attachment (Al) with Nozzle Extension (Al),

Semicircular Slot (A2) with a striking area (a"),

Semicircular block (A3); and

Mouthpiece (A4) with a first opening (a) and a second opening (a'). Said Third Assembly (TA) is an interlocking assembly for interlocking said First Assembly (FA) and said Second Assembly (SA) wherein said Third Assembly (TA) comprises of:

First Slot (S I) on the Passage wall (W2) of the Actuator (Ac) in said First Assembly (FA) and

Second Slot (S2) on said Attachment (A) of said Second Assembly (SA) .

An improved inhaler (I) as claimed in claim 1 , wherein said Second Assembly (SA) is a detachable attachment (A) that is connected to said First Assembly (FA) .

An improved inhaler (I) as claimed in claim 1 and 2, wherein said Nozzle Extension (Al) of said Second Assembly (SA) is fixed with the Nozzle (N) of said First Assembly (FA) through male-female joining mechanism (Ν'- Α ) thereby forming an extended Nozzle.

An improved inhaler (I) as claimed in claim 1 to 3, wherein said Semicircular Slot (A2) is provided around a Semicircular block (A3) in said Attachment (A) and said Semicircular Slot (A2) consists of a striking area (a") . An improved inhaler (I) as claimed in claim 1 to 4, wherein said semicircular slot (A2) ends in a first opening (a) and a second opening (a') in said mouth piece (A4).

An improved inhaler (I) as claimed in claim 1 to 5, wherein said first slot (S I) is elevated portion conjoined to passage area (P) of said actuator (Ac); wherein further said passage area (P) comprises of pair of said first slot (S I) placed on opposite side within said passage area (P) in parallel direction, placed equidistant from the end of the passage area (P) .

An improved inhaler (I) as claimed in claim 1 to 6, wherein said second slot (S2) is elevated portion conjoined to said mouthpiece (A4) of the Attachment (A); wherein further second slot (S2) is placed in pair in parallel direction on opposite side on mouthpiece (A4) of the Attachment (A).

Claims

CLAIMS:

1. An improved inhaler (I) mainly comprises of:

First Assembly (FA),

Second Assembly (SA),

Third Assembly (TA), and

Mouthpiece Cap (MC);

Wherein:

Actuator walls (W l),

Adapter (E),

Nozzle (N),

Passage (P) and

Passage wall (W2);

Actuator walls (W l), Adapter (E),

Nozzle (N),

Horizontal Restricting Wall (H),

Grovel Shaped Restricting Wall (G),

Passage (P) and

Passage wall (W2) .

Semicircular Slot

(A2) with a striking area (a"),

Semicircular block

(A3); and

Mouthpiece

(A4) with a first opening (a) and a second opening (a'). Said Third Assembly (TA) is an interlocking assembly for interlocking said First Assembly (FA) and said Second Assembly (SA) wherein said Third Assembly (TA) comprises of:

Second Slot (S2) on said Attachment (A) of said Second Assembly (SA) .

An improved inhaler (I) as claimed in claim 1 to 3, wherein said Semicircular Slot (A2) is provided around a Semicircular block (A3) in said Attachment (A) and said Semicircular Slot (A2) consists of a striking area (a") .

5. An improved inhaler (I) as claimed in claim 1 to 4, wherein said semicircular slot (A2) ends in a first opening (a) and a second opening (a') in said mouth piece (A4).

6. An improved inhaler (I) as claimed in claim 1 to 5, wherein said first slot (S I) is elevated portion conjoined to passage area (P) of said actuator (Ac); wherein further said passage area (P) comprises of pair of said first slot (S I) placed on opposite side within said passage area (P) in parallel direction, placed equidistant from the end of the passage area (P) .

7. An improved inhaler (I) as claimed in claim 1 to 6, wherein said second slot (S2) is elevated portion conjoined to said mouthpiece (A4) of the Attachment (A); wherein further second slot (S2) is placed in pair in parallel direction on opposite side on mouthpiece (A4) of the Attachment (A).